Learn which common medications you need to avoid when you have oHCM, including some for blood pressure and erectile ...

Please provide your email address to receive an email when new articles are posted on . Mavacamten presents dosing and drug-drug interaction challenges. A multidisciplinary approach featuring a ...

Approved pharmacologic therapies for pediatric hypertrophic cardiomyopathy are lacking, and surgical intervention may be indicated in patients with left ventricular outflow tract obstruction. The ...

Please provide your email address to receive an email when new articles are posted on . A first-in-human phase 1 trial is testing a novel gene therapy for hypertrophic cardiomyopathy. The one-time ...

Living with any kind of heart-related disease can be worrisome, especially one with a range of symptoms, such as obstructive hypertrophic cardiomyopathy (HCM). This genetic condition causes a ...

If your current medications aren’t doing enough to manage your obstructive hypertrophic cardiomyopathy (HCM), your cardiologist may recommend mavacamten (Camzyos). The drug helps your heart relax, ...

Tenaya Therapeutics reports positive preclinical data for TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy, published in Nature Communications. Tenaya Therapeutics, Inc. has ...

Credit: Getty Images HCM is a genetic disease, usually caused by mutations in sarcomere proteins such as myosin, actin, tropomyosin, and myosin-binding protein C. Hypertrophic cardiomyopathy (HCM) ...

Beta-blockers have been the initial treatment for symptomatic obstructive hypertrophic cardiomyopathy (HCM) despite limited evidence of their efficacy. Aficamten is a cardiac myosin inhibitor that ...

Myqorzo (aficamten) is an oral medicine used for people with obstructive hypertrophic cardiomyopathy (oHCM). Hypertrophic cardiomyopathy (HCM) is an inherited condition (passed down in families) that ...

Mavacamten treatment in oHCM patients led to new atrial fibrillation/flutter and heart failure, with frequent acute care episodes within months. Nearly half of the patients required dose adjustments, ...